Announces Seven Year Extension of Proton Therapy Lease Agreement with Orlando Health Through 2033Conference Call Scheduled ...
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results